

Brendan M Everett

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5425845/brendan-m-everett-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65
papers

9,604
citations

34
h-index

73
g-index

73
ext. papers

13,425
ext. citations

12.7
avg, IF

5.89
L-index

#	Paper	IF	Citations
65	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial.. <i>JAMA - Journal of the American Medical Association</i> , 2022 , 327, 227-236	27.4	18
64	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.. <i>Annals of Internal Medicine</i> , 2022 , 175, W4	8	
63	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.. <i>Annals of Internal Medicine</i> , 2022 , 175, W4-W5	8	
62	Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	2
61	Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 1703-1712	27.4	36
60	Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications. <i>Rheumatology</i> , 2021 , 60, 3789-3798	3.9	1
59	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021 , 385, 790-802	59.2	203
58	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021 , 385, 777-789	59.2	227
57	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2021 , 174, 1528-1541	8	8
56	Comparative Risks of Cardiovascular Disease in Patients With Systemic Lupus Erythematosus, Diabetes Mellitus, and in General Medicaid Recipients. <i>Arthritis Care and Research</i> , 2020 , 72, 1431-1439	4.7	9
55	Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. <i>BMJ, The</i> , 2020 , 370, m2812	5.9	6
54	Atrial Fibrillation/flutter Hospitalizations among US Medicaid Recipients with and without Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2020 , 47, 1359-1365	4.1	6
53	Comparison of an administrative algorithm for SLE disease severity to clinical SLE Disease Activity Index scores. <i>Rheumatology International</i> , 2020 , 40, 257-261	3.6	7
52	Adverse Effects of Low-Dose Methotrexate: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2020 , 172, 369-380	8	52
51	2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1117-1145	15.1	124
50	Markers of Myocardial Stress, Myocardial Injury, and Subclinical Inflammation and the Risk of Sudden Death. <i>Circulation</i> , 2020 , 142, 1148-1158	16.7	6
49	Targeting Inflammation to Reduce Residual Cardiovascular Risk. <i>Current Atherosclerosis Reports</i> , 2020 , 22, 66	6	11

48	Inhibition of Interleukin-1 β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1660-1670	15.1	43
47	Medicaid Expansion and Utilization of Antihyperglycemic Therapies. <i>Diabetes Care</i> , 2020 , 43, 2684-2690	14.6	3
46	Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017. <i>JAMA Internal Medicine</i> , 2020 , 180, 141-144	11.5	14
45	Initial disease severity, cardiovascular events and all-cause mortality among patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2020 , 59, 495-504	3.9	8
44	Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 389-395	5.3	11
43	Dyslipidemia Profiles in Patients with Peripheral Artery Disease. <i>Current Cardiology Reports</i> , 2019 , 21, 42	4.2	11
42	Novel Antiatherosclerotic Therapies. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019 , 39, 538-545	5.4	58
41	Racial/ethnic variation in stroke rates and risks among patients with systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 840-846	5.3	12
40	Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> , 2019 , 42, 2298-2306	14.6	70
39	Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. <i>New England Journal of Medicine</i> , 2019 , 380, 752-762	59.2	538
38	Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. <i>Circulation</i> , 2019 , 139, 1289-1299	16.7	223
37	Lipid Testing and Statin Prescriptions Among Medicaid Recipients With Systemic Lupus Erythematosus or Diabetes Mellitus and the General Medicaid Population. <i>Arthritis Care and Research</i> , 2019 , 71, 104-115	4.7	10
36	Impact of Changes in Inflammation on Estimated Ten-Year Cardiovascular Risk in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1392-1398	9.5	8
35	Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. <i>BMJ, The</i> , 2018 , 360, k119	5.9	93
34	Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2392-2401	15.1	170
33	Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). <i>European Heart Journal</i> , 2018 , 39, 3499-3507	9.5	233
32	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. <i>Lancet, The</i> , 2018 , 391, 319-328	40	430
31	2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 2200-2223	15.1	180

30	Hypoglycemia and Elevated Troponin in Patients With Diabetes and Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1778-1786	15.1	18
29	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. <i>American Heart Journal</i> , 2018 , 206, 80-93	4.9	183
28	Relationship of Interleukin-1 Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial. <i>Annals of Internal Medicine</i> , 2018 , 169, 535-542	8	51
27	Reply: Inflammatory Pathways in CVD and Diabetes: Broad-Spectrum Versus Selective Targeting. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1432-1433	15.1	0
26	Inhibition of Interleukin-1 by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2405-2414	15.1	114
25	Race/Ethnicity and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1823-1831	9.5	44
24	Effect of interleukin-1 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2017 , 390, 1833-1842	4.0	634
23	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 1119-1131	59.2	3877
22	Cardiac troponin as a novel tool for cardiovascular risk prediction in ambulatory populations. <i>Trends in Cardiovascular Medicine</i> , 2017 , 27, 41-47	6.9	5
21	Association Between Markers of Inflammation and Total Stroke by Hypertensive Status Among Women. <i>American Journal of Hypertension</i> , 2016 , 29, 1117-24	2.3	11
20	Impact of Modifiable Risk Factors on B-type Natriuretic Peptide and Cardiac Troponin T Concentrations. <i>American Journal of Cardiology</i> , 2016 , 117, 376-81	3	9
19	Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. <i>European Heart Journal</i> , 2016 , 37, 2428-37	9.5	140
18	Finding Efficacy in a Safety Trial: Empagliflozin and Cardiovascular Death. <i>Circulation</i> , 2016 , 134, 773-5	16.7	3
17	Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. <i>Lancet Diabetes and Endocrinology, the</i> , 2016 , 4, 840-9	18.1	108
16	High-sensitivity cardiac troponin I and B-type natriuretic Peptide as predictors of vascular events in primary prevention: impact of statin therapy. <i>Circulation</i> , 2015 , 131, 1851-60	16.7	80
15	Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs. <i>New England Journal of Medicine</i> , 2015 , 373, 1588-91	59.2	97
14	Interaction of impaired coronary flow reserve and cardiomyocyte injury on adverse cardiovascular outcomes in patients without overt coronary artery disease. <i>Circulation</i> , 2015 , 131, 528-35	16.7	99
13	Novel genetic markers associate with atrial fibrillation risk in Europeans and Japanese. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1200-1210	15.1	102

12	B-type natriuretic peptides improve cardiovascular disease risk prediction in a cohort of women. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1789-97	15.1	20
11	Response to letter regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)". <i>Circulation</i> , 2014 , 130, e152	16.7	2
10	Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. <i>American Heart Journal</i> , 2013 , 166, 199-207.e15	4.9	276
9	Effects of interleukin-1 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. <i>Circulation</i> , 2012 , 126, 2739-48	16.7	374
8	Sensitive cardiac troponin T assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus: the Women's Health Study. <i>Circulation</i> , 2011 , 123, 2811-8	16.7	86
7	Physical activity and the risk of incident atrial fibrillation in women. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011 , 4, 321-7	5.8	74
6	Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). <i>Circulation</i> , 2010 , 121, 143-50	16.7	135
5	Interleukin-18 and the risk of future cardiovascular disease among initially healthy women. <i>Atherosclerosis</i> , 2009 , 202, 282-8	3.1	27
4	Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial. <i>Clinical Therapeutics</i> , 2008 , 30, 661-72	3.5	26
3	Using inflammatory biomarkers to guide lipid therapy. <i>Current Cardiovascular Risk Reports</i> , 2008 , 2, 29-34.	9	2
2	Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. <i>Annals of Thoracic Surgery</i> , 2007 , 83, 592-7	2.7	61
1	The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 2235-42	15.1	97